Management of patients with acute hyperkalemia

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 15, 2010, Pages 1631-1635

  Elliott, Meghan J ^a   Ronksley, Paul E ^a   Clase, Catherine M ^b   Ahmed, Sofia B ^a   Hemmelgarn, Brenda R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPHYLLINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BICARBONATE; FLUDROCORTISONE; HYDROCHLOROTHIAZIDE; INSULIN; LANSOPRAZOLE; LEVALBUTEROL; METFORMIN; RAMIPRIL; RESIN; SALBUTAMOL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; POTASSIUM;

AGED; ANXIETY DISORDER; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; FATIGUE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HEART RATE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; MALE; MIGRAINE; PEPTIC ULCER; SIDE EFFECT; TREMOR; WEAKNESS; ACUTE DISEASE; BLOOD; DRUG COMBINATION;

ACUTE DISEASE; ADRENERGIC BETA-AGONISTS; AGED; DRUG THERAPY, COMBINATION; HUMANS; HYPERKALEMIA; INSULIN; MALE; POTASSIUM;

EID: 78049275343     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.100461     Document Type: Article

References (37)

1. Moore ML, Bailey RR. Hyperkalaemia in patients in hospital. N Z Med J 1989;102:557-8.
2. Stevens MS, Dunlay RW. Hyperkalemia in hospitalized patients. Int Urol Nephrol 2000;32:177-80.
3. Paice B, Gray JM, McBride D, et al. Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed) 1983;286:1189-92.
4. Shemer J, Modan M, Ezra D, et al. Incidence of hyperkalemia in hospitalized patients. Isr J Med Sci 1983;19:659-61.
5. Acker CG, Johnson JP, Palevsky PM, et al. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998;158:917-24.
6. Indermitte J, Burkolter S, Drewe J, et al. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients. Drug Saf 2007;30:71-80. (Pubitemid 46072359)
7. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.
8. Surawicz B. Relationship between electrocardiogram and electrolytes. Am Heart J 1967;73:814-34.
9. Freeman K, Feldman JA, Mitchell P, et al. Effects of presentation and electrocardiogram on time to treatment of hyperkalemia. Acad Emerg Med 2008;15:239-49.
10. Fisch C. Relation of electrolyte disturbances to cardiac arrhythmias. Circulation 1973;47:408-19.
11. Alfonzo AV, Isles C, Geddes C, et al. Potassium disorders - clinical spectrum and emergency management. Resuscitation 2006;70:10-25. (Pubitemid 43903048)
12. Weisberg LS. Management of severe hyperkalemia. Crit Care Med 2008;36:3246-51.
13. Iqbal Z, Friedman EA. Preferred therapy of hyperkalemia in renal insufficiency: survey of nephrology training-program directors. N Engl J Med 1989;320:60-1. (Pubitemid 19033066)
14. Mahoney BA, Smith WA, Lo DS, et al. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev 2005;(2):CD003235.
15. Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. 2nd ed. London (UK): BMJ Publishing Group; 2001.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-W69.
18. Kocoglu H, Goksu S, Pence S, et al. Treatment of hyperkalemia with high dose intravenous insulin during extracorporeal circulation. Cardiovasc Eng 2003;8:40-3. (Pubitemid 37047457)
19. Mushtaq MA, Masood M. Treatment of hyperkalemia with salbutamol and insulin. Pak J Med Sci 2006;22:176-9.
20. Kim DM, Chung JH, Yoon SH, et al. Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis. Nephrol Dial Transplant 2007;22:3273-6.
21. Pancu D, LaFlamme M, Evans E, et al. Levalbuterol is as effective as racemic albuterol in lowering serum potassium. J Emerg Med 2003;25:13-6.
22. Balanzario JM, Nuevo JJL, Gaeta DEH, et al. Efecto del salbutamol intravenoso vs salbutamol en micronebulizador en la hipercaliemia por insuficiencia renal cronica. Med Int Mex 2003;19:202-5.
23. Capdevila M, Ruiz IM, Ferrer C, et al. The efficiency of potassium removal during bicarbonate hemodialysis. Hemodial Int 2005;9:296-302.
24. Heguilen RM, Sciurano C, Bellusci AD, et al. The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic haemodialysis patients. Nephrol Dial Transplant 2005;20:591-7.
25. Kaisar MO, Wiggins KJ, Sturtevant JM, et al. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients. Am J Kidney Dis 2006;47:809-14.
26. Li Q, Zhou MT, Wang Y, et al. Effect of insulin on hyperkalemia during anhepatic stage of liver transplantation. World J Gastroenterol 2004;10:2427-9.
27. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med 1989;110:426-9.
28. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990;38:869-72.
29. Allon M, Shanklin N. Effect of albuterol treatment on subsequent dialytic potassium removal. Am J Kidney Dis 1995;26:607-13.
30. Allon M, Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis 1996;28:508-14.
31. Ngugi NN, McLigeyo SO, Kayima JK. Treatment of hyperkalaemia by altering the transcellular gradient in patients with renal failure: effect of various therapeutic approaches. East Afr Med J 1997;74:503-9.
32. Gruy-Kapral C, Emmett M, Santa Ana CA, et al. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 1998;9:1924-30.
33. Mandelberg A, Krupnik Z, Houri S, et al. Salbutamol metered-dose inhaler with spacer for hyperkalemia: How fast? How safe? Chest 1999;115:617-22.
34. Mahajan SK, Mangla M, Kishore K. Comparison of aminophylline and insulin-dextrose infusions in acute therapy of hyperkalemia in end-stage renal disease patients. J Assoc Physicians India 2001;49:1082-5.
35. Zehnder C, Gutzwiller JP, Huber A, et al. Low-potassium and glucose-free dialysis maintains urea but enhances potassium removal. Nephrol Dial Transplant 2001;16:78-84.
36. Gutzwiller JP, Schneditz D, Huber AR, et al. Increasing blood flow increases kt/V(urea) and potassium removal but fails to improve phosphate removal. Clin Nephrol 2003;59:130-6.
37. ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 10.1: Life-threatening electrolyte abnormalities. Circulation 2005;112(24 Suppl I):IV121-5.